Home › Funds › Venrock Adviser, LLC › SYRE

Venrock Adviser, LLC position in SYRE

SPYRE THERAPEUTICS INC · Health Care

Venrock Adviser, LLC reported holding 2,985,448 shares of SYRE (SPYRE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$265.0M, representing 8.04% of its reported portfolio and ranking #4 among its reported holdings. Venrock Adviser, LLC has disclosed SYRE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)2.99M sh
Reported value held$265.05M
Portfolio Weight8.04%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Venrock Adviser, LLC's SYRE position evolved

Venrock Adviser, LLC first disclosed a stake in SYRE in Q4 2023 at 2,372,714 shares (US$51.1M). The position peaked in Q2 2026 at 2,985,448 shares, worth US$265.0M. Across 11 filings, Venrock Adviser, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 2,985,448 shares valued at US$265.0M — a reduction of -700,000 shares quarter over quarter.. Notable position changes include a 37% increase in Q4 2025 (shares rose 54% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 2.37M $51.06M New
Q1 2024 2.17M $82.38M Reduce
Q2 2024 2.69M $63.13M Add
Q3 2024 2.69M $78.98M Hold
Q4 2024 2.69M $62.52M Hold
Q1 2025 2.69M $43.33M Hold
Q2 2025 2.69M $40.20M Hold
Q3 2025 2.69M $45.01M Hold
Q4 2025 3.69M $120.74M Add
Q1 2026 3.69M $185.89M Hold
Q2 2026 2.99M $265.05M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SYRE and 13F data

SYRE (SPYRE THERAPEUTICS INC) is a Health Care company. 70 other funds we track also report a position in SYRE — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$383.5M), RTW INVESTMENTS, LP (US$377.5M), Paradigm Biocapital Advisors LP (US$341.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SYRE

All SYRE fund holders →

FAQ

How long has Venrock Adviser, LLC held SYRE?

Venrock Adviser, LLC has disclosed SYRE holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is Venrock Adviser, LLC's current position in SYRE?

As of Q2 2026, Venrock Adviser, LLC holds 2.99M shares of SYRE (SPYRE THERAPEUTICS INC), valued at $265.05M, representing 8.04% of its reported portfolio and ranking #4.

Has Venrock Adviser, LLC been buying or selling SYRE?

In the latest 13F filing (Q2 2026), Venrock Adviser, LLC reduced its position in SYRE. The position peaked in Q2 2026 at 2.99M shares.

Which other funds hold SYRE?

Other major institutional holders of SYRE include PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.